You are viewing the site in preview mode

Skip to main content

Advertisement

Table 6 Health state utilities for HCV patients achieving SVR

From: Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

Method Study Value Difference
SVR Non-response/relapse
EQ5D Thein et al. 2005 [93] 0.83
  Chong et al. 2003 [95] 0.83 0.76c 0.07
  Van Rooijen et al. 2011 [99] 0.84 0.70 0.14
SF-36 Thein et al. 2005 [93] 0.74–0.90 0.70–0.86b 0.04–0.05
SF-6D Hsu et al. 2012 [103] 0.71 0.66c 0.05
  John-Baptiste et al. 2009 [18] 0.71 0.65 0.06
HUI3 Thein et al. 2005 [93] 0.77
  John-Baptiste et al. 2009 [18] 0.70 0.58 0.12
  Hsu et al. 2012 [103] 0.70 0.57c 0.13
HUI Chong et al. 2003 [95] 0.77 0.73c 0.04
TTO John-Baptiste et al. 2009 [18] 0.89 0.84 0.05
  Hsu et al. 2012 [103] 0.88 0.80c 0.08
SG Thein et al. 2005 [93] 0.86
  Chong et al. 2003 [95] 0.86 0.79c 0.08
VAS Thein et al. 2005 [93] 0.74
  Chong et al. 2003 [95] 0.74 0.70c 0.04
Not stated Liu et al. 2012 [104] 0.933–1.00a
  Chhatwal et al. 2013 [105] 1.00
  1. HUI3, Health Utilities Index Mark 3; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; SG, standard gamble; TTO, time trade off; VAS, visual analog scale.
  2. aAge-specific quality of life weight.
  3. bUntreated.
  4. cPatients with mild/moderate HCV or chronic infection.